Advertisement

  • Loading metrics

Open Access

Review

Telomere Length and the Cancer–Atherosclerosis Trade-Off

  • Rivka C. Stone ,

    rivky83@gmail.com

    Affiliation The Center of Human Development and Aging, New Jersey Medical School, Rutgers, Newark, New Jersey, United States of America

    ⨯
  • Kent Horvath,

    Affiliation The Center of Human Development and Aging, New Jersey Medical School, Rutgers, Newark, New Jersey, United States of America

    ⨯
  • Jeremy D. Kark,

    Affiliation Epidemiology Unit, Hebrew University–Hadassah School of Public Health and Community Medicine, Jerusalem, Israel

    ⨯
  • Ezra Susser,

    Affiliations Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America, New York State Psychiatric Institute, New York, New York, United States of America

    ⨯
  • Sarah A. Tishkoff,

    Affiliations Department of Genetics, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

    ⨯
  • Abraham Aviv

    Affiliation The Center of Human Development and Aging, New Jersey Medical School, Rutgers, Newark, New Jersey, United States of America

    ⨯

Abstract

Modern humans, the longest-living terrestrial mammals, display short telomeres and repressed telomerase activity in somatic tissues compared with most short-living small mammals. The dual trait of short telomeres and repressed telomerase might render humans relatively resistant to cancer compared with short-living small mammals. However, the trade-off for cancer resistance is ostensibly increased age-related degenerative diseases, principally in the form of atherosclerosis. In this communication, we discuss (a) the genetics of human telomere length, a highly heritable complex trait that is influenced by genetic ancestry, sex, and paternal age at conception, (b) how cancer might have played a role in the evolution of telomere biology across mammals, (c) evidence that in modern humans telomere length is a determinant (rather than only a biomarker) of cancer and atherosclerosis, and (d) the potential influence of relatively recent evolutionary forces in fashioning the variation in telomere length across and within populations, and their likely lasting impact on major diseases in humans. Finally, we propose venues for future research on human telomere genetics in the context of its potential role in shaping the modern human lifespan.

Citation: Stone RC, Horvath K, Kark JD, Susser E, Tishkoff SA, Aviv A (2016) Telomere Length and the Cancer–Atherosclerosis Trade-Off. PLoS Genet 12(7): e1006144. https://doi.org/10.1371/journal.pgen.1006144

Editor: Elizabeth M. C. Fisher, University College London, UNITED KINGDOM

Published: July 7, 2016

Copyright: © 2016 Stone et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by awards from the National Institutes of Health to Dr. Ezra Susser (R01HD071180), Dr. Sarah Tishkoff (R01GM113657, R01DK104339), and Dr. Abraham Aviv (R01HL116446, R01HD071180). The funders had no role in the preparation of the article.

Competing interests: The authors have declared that no competing interests exist.

Introduction

In mammals, telomeres consist of TTAGGG tandem repeats and their binding proteins, which together cap and protect the ends of chromosomes [1]. Telomeres experience progressive shortening with successive cell replications, ultimately reaching a critically short length, triggering replicative senescence, which might be one of the mechanisms that drive aging of tissues and organs in vivo [2,3]. A body of data exists on telomere length (TL) dynamics (TL and its age-dependent attrition) and the association of TL with human diseases. These include a number of aging-related disorders that belong to the two disease categories that largely shape the lifespan of humans in high- and middle-income countries: cancer and atherosclerotic cardiovascular disease (CVD). Still, a clear conceptual framework for the role of telomere biology in the evolution of human health and disease is lacking. Moreover, earlier research promoted the view that short TL, as expressed in leukocytes, is a non-causal biomarker of increased risk for aging-related diseases. In contrast, more recent research based on the analysis of genetic determinants of TL and on Mendelian randomization studies using single nucleotide polymorphisms (SNPs) as proxies for TL suggests that TL might play a causal role in a number of cancers [4–6] and in atherosclerotic CVD [7].

General Characteristics of Telomere Length in Humans

Homo sapiens displays short TL compared with most other mammalian species [8] and repressed activity in somatic tissues of telomerase [8–10], the reverse transcriptase that uses its RNA template to add telomere repeats to the DNA termini [1]. During fetal development, a similar TL is maintained across somatic cells [11,12], including cells in the hematopoietic system [13]. That is, fetuses and newborns with short (or long) TL in one tissue display short (or long) TL in other tissues. During postnatal growth and development, some tissues exhibit more TL shortening than others; for example, there is more TL attrition in the highly proliferative hematopoietic system than in much less proliferative muscle tissue. However, the similarity in TL across tissues that has been established by adulthood is largely maintained over the remaining life course [14].

Knowledge of TL dynamics in humans is primarily based on research using leukocytes. Leukocyte TL (LTL) is highly familial with about 65% heritability; the heritability of age-dependent LTL attrition (in adults) is about 30% [15–18]. In addition, sex (females have longer LTL than males [16,19,20]), ancestry (African Americans [21] and sub-Saharan Africans [22] have longer LTL than individuals of European ancestry), and father’s age at conception (offspring of older fathers have longer LTL than those of younger fathers [23–26]) also influence LTL. Environmental factors, including socioeconomic status [27], smoking [19,28], sedentary lifestyle [29], energy intake [30], and perhaps mental stress [31,32] might be associated with a short LTL, suggesting that these factors might influence or be influenced by LTL dynamics to some extent.

On average, mean LTL at birth is 9.5 kb in Europeans with a wide range of variation across newborns [11,33,34]. Although LTL undergoes progressive shortening with age, the LTL variance observed in newborns is largely maintained during the life course [11,14]. At the age of 20 years, mean LTL is about 7.8 kb. Thereafter, the average LTL attrition approximates 25 base pairs per year [35]. Little is known about inter-individual variation in LTL attrition during growth and development based on longitudinal study design. Longitudinal studies show that LTL attrition during adulthood does vary across individuals within a given population, but for the overwhelming majority of the population, the inter-individual variation in this attrition is typically of a magnitude that is insufficient to produce a substantial change in an individual’s LTL percentile ranking compared with peers [36]. Based on the findings in fetuses [12], newborns [11,13,33,34], and adults [14,36,37], and on modeling of LTL attrition during growth [38], we infer that LTL at birth is a major determinant of LTL in adults, such that newborns with short (or long) LTL are likely to have short (or long) LTL throughout their life course [39,40].

The Genetics of Leukocyte Telomere Length

LTL is a complex genetic trait. A series of population-based genome-wide association studies (GWAS) has identified genetic loci associated with LTL. To date, 11 LTL-associated loci have been identified in cohorts of Europeans [7,41–44], and many more genetic loci associated with LTL remain to be identified and characterized across populations. Some of the loci that have already been found to be associated with LTL harbor genes that are engaged in telomere maintenance. These include genes encoding the two major subunits of telomerase, the telomerase reverse transcriptase (TERT) and its RNA component (TERC), two of the members of the human CST (CTC1, STN1, and TEN1) complex, i.e., CTC1 and STN1 (OBFC1), telomerase ribonucleoprotein nuclear assembly factor 1 (NAF1), and telomere length maintenance gene regulator of telomere helicase 1 (RTEL1) [7,41,42,44]. The exact roles of several other LTL-associated genes in TL regulation are poorly understood; these include zinc finger proteins ZNF208 and ZNF676, neutrophil trafficking chemokine CXCR4, and DCAF4, which is involved in the ultraviolet radiation-induced DNA damage response [7,42–44].

Major germ line mutations can cause critically short telomeres that might lead to bone marrow failure. For example, mutations in TERT and TERC as well as in telomere end-protective shelterins (telomeric repeat binding factor 1 [TERF1] and TRF1-interacting nuclear factor 2 [TINF2]) lead to extremely short telomeres and the development of dyskeratosis congenita and idiopathic pulmonary fibrosis, which typically present with aplastic anemia [45]. However, these telomeropathies are uncommon and may not explain telomere-related diseases in the general population.

Cancer as an Evolutionary Force Affecting Telomere Length

TL genetics should be considered in the context of evolutionary forces that have left their signature on the human genome. Inspection of the human genome reveals that of the approximately 22,000 currently annotated genes, 13,000 genes (about 60%) are linked to biological pathways of “cancer” (as referenced in the Ingenuity Knowledge Base [www.ingenuity.com]). These include genes engaged in growth, development, tissue regeneration, and tissue renewal, which heighten cancer risk due to increased cell replication, and genes that suppress cancer, including those that ultimately promote senescence and apoptosis [46]. Central among cancer-protective pathways might be telomere-driven replicative senescence [47].

Stem cells are likely to undergo more replications in large, long-living mammals than in small, short-lived ones; this is because more replications are necessary for developing and maintaining a larger body size. More cell replication confers increased risk of cancer through accumulating de novo somatic mutations, which happen during successive DNA replications. This concept is supported by work showing that the risk of developing major human cancers is related to the number of stem cell divisions occurring in the tissues from which the cancers originated [48,49]. Yet, large, long-living mammals generally display no increase in cancer risk compared to small, short-lived ones, a phenomenon known as Peto’s paradox [50], suggesting that mechanisms have evolved to mitigate cancer risk in tandem with increasing body size and longevity [51,52]. One such mechanism has been described in elephants. The elephant genome contains many more copies of TP53, a potent DNA damage response and tumor suppressor gene; p53-dependent apoptosis is thus triggered at a lower threshold of accumulating mutations, conferring cellular resistance to oncogenic transformation [53].

Similarly, a telomere-linked mechanism has been proposed in mammals based upon observations that telomerase activity in somatic tissues tends to be inversely correlated with body size [9,10] while TL is inversely related to lifespan [8]. Repressed telomerase and short telomeres would, therefore, limit replicative capacity in humans. In this way, short TL might curb the accumulation of de novo mutations and reduce the probability of oncogenic transformation in large, long-living mammals.

Given the wide variation in TL across humans, might longer telomeres increase cancer risk? While initial studies were inconsistent (perhaps partially due to flaws in study design and small sample sizes [54]), more recent studies show that in individuals of European ancestry, long telomeres, as expressed in LTL, are associated with increased risk for melanoma [4,55,56], adenocarcinoma of the lung [57–59], and cancers of the breast ([60], but see [61]), pancreas [62], and prostate [63]. Moreover, Mendelian randomization studies using LTL-associated SNPs support the inference that having a longer LTL has a causal relation to cancer risk [5,6].

Polygenetic Adaptation and Telomere Length

Complex traits that are influenced by multiple genetic loci may be targets of polygenic adaptation [64,65], i.e., simultaneous shifts in frequencies of many alleles influencing a trait in response to local adaptation during human evolutionary history. Collectively, however, these alleles might ultimately explain a large proportion of the wide variation in LTL across humans. An illustration of this concept comes from findings that individuals of European ancestry display shorter LTL than sub-Saharan Africans and African Americans, and that loci associated with LTL show evidence of polygenic adaptation in Europeans compared to Africans [22].

Dark skin renders protection to Africans from the DNA-damaging effect of ultraviolet radiation (UVR); such damage is a major risk factor for melanoma [66]. The northbound migration out of Africa approximately 20–40 thousand years ago was ostensibly associated with skin depigmentation and thus increased sensitivity to UVR, which might have augmented the risk of melanoma. The idea that melanoma acted as an evolutionary selective force in ancestral humans has been challenged based on the assumption that the life span of ancestral humans was relatively short, and melanoma principally strikes individuals during the post-reproductive years [67]. However, this view does not consider that once surviving childhood, ancestral humans lived much longer than originally thought, and considerable evidence indicates that melanoma afflicts adults throughout the life course, including young adulthood [68]. One mechanism whereby individuals with light skin might have attenuated the risk of melanoma is by shortening their telomeres through polygenic adaptation, thereby explaining in part the shorter LTL in individuals of European ancestry than in sub-Saharan Africans [22]. Simply put, Europeans would have been even more susceptible to melanoma without polygenetic adaptation-mediated TL shortening.

The Cancer–Atherosclerosis Trade-Off

The cancer protection conferred by short telomeres could come with an evolutionary trade-off [69], namely, diminished proliferative activity of stem cells and consequently less regenerative capacity. This would manifest in age-dependent degenerative diseases. Some of the leading degenerative diseases in humans are related to atherosclerosis, and atherosclerosis is associated with short LTL [40,70,71]. As cancer and atherosclerosis strongly impact longevity, the diametrically opposing roles of TL in these two disorders might be relevant to understanding the lifespan of contemporary humans and future trajectories in life expectancy. Notably, in evolutionary terms, this would probably have become more relevant when agrarian societies emerged over the past ten thousand years or so and lifespans increased considerably. In fact, evidence of atherosclerosis has been detected in ancient human Egyptian mummies [72].

Recent studies have used LTL GWAS findings to generate “genetic risk scores” for cancers and for atherosclerosis insofar as it is expressed in coronary heart disease. These studies have shown that the same cluster of LTL-associated alleles (OBFC1, ZNF208, TERC, TERT, RTEL1, ACTP2, and NAF1) is a risk indicator for melanoma [4], lung cancer [57], and coronary heart disease [7], such that when the joint effect of the alleles results in a comparatively long LTL, the risk for melanoma and lung cancer is increased, whereas the risk for coronary heart disease is diminished. The opposite holds when the joint effect of the alleles results in a comparatively short LTL, which engenders a higher risk for coronary heart disease and a lower risk for cancer (Fig 1). This cancer–atherosclerosis trade-off might principally apply to contemporary humans because they live so long, but not to ancestral humans.

thumbnail
Download:
Fig 1. Telomere length (TL) and the cancer–atherosclerosis trade-off at the genomic level.

Alleles that are jointly associated with relatively short TL diminish the risk for major cancers and increase the risk for atherosclerosis, while alleles (of the same SNPs) that are jointly associated with relatively long TL increase the risk for major cancers and diminish the risk for atherosclerosis.

https://doi.org/10.1371/journal.pgen.1006144.g001

Ancestry, Telomere Length, and the Cancer–Atherosclerosis Trade-Off

In light of the longer LTL in African Americans than in individuals of European ancestry, it is of interest to compare the incidence of major cancers and atherosclerosis in the two ethnicities. The incidence of cancers of the lung (after adjustment for smoking), pancreas, and prostate is higher in African Americans than in individuals of European ancestry [73–75]. The incidence of triple-negative breast cancer is also higher in African American women, and its onset is at a younger age than in women of European ancestry [76]. In contrast, in spite of increased risk factors for atherosclerosis due to higher rates of type 2 diabetes, hypertension, left ventricular hypertrophy, and low socioeconomic status, African Americans display a lower incidence of atherosclerosis, as expressed in coronary artery calcification and coronary artery disease [77,78].

Conclusions and Suggestions for Future Research

Converging lines of evidence point to a causal role of TL in the cancer–atherosclerosis trade-off across humans. This trade-off has been principally established through the force of evolution. In contrast to cancer, which is associated with over ten thousand genes, only several hundred genes in the human genome have been shown to relate to atherosclerosis. Yet, atherosclerosis is a major determinant in the longevity of humans because of their relatively long lifespan, especially in high- and middle-income societies.

We note, however, the paucity of comparative LTL data by ethnicity and that LTL GWAS have been almost exclusively performed on individuals of European ancestry. Moreover, the role of TL in the cancer–atherosclerosis trade-off has been shown thus far based on a few types of cancers and an aggregate of less than a dozen SNPs. There are likely numerous other SNPs throughout the genome that are associated with TL, and distinctive TL-mediated evolutionary trade-offs have probably emerged within different global populations and at different periods to accommodate their unique environmental settings. Therefore, large-scale measurements of LTL and genome-wide genotyping (sequencing) of different ethnic groups residing in diverse geographical regions across the globe will be essential to decipher the evolutionary signature in human telomere biology and to gain further insight into the role of telomeres in human diseases.

References

  1. 1. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS letters. 2005;579(4):859–62. pmid:15680963.
  2. 2. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutation research. 1991;256(2–6):271–82. Epub 1991/03/01. pmid:1722017.
  3. 3. van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439–46. pmid:24848057; PubMed Central PMCID: PMC4214092.
  4. 4. Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, et al. The effect on melanoma risk of genes previously associated with telomere length. Journal of the National Cancer Institute. 2014;106(10). pmid:25231748; PubMed Central PMCID: PMC4196080.
  5. 5. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015;6(40):42468–77. pmid:26646793; PubMed Central PMCID: PMC4767445.
  6. 6. Zhang C, Doherty JA, Burgess S, Hung RJ, Lindstrom S, Kraft P, et al. Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Human molecular genetics. 2015;24(18):5356–66. pmid:26138067; PubMed Central PMCID: PMC4550826.
  7. 7. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nature genetics. 2013;45(4):422–7, 7e1–2. Epub 2013/03/29. pmid:23535734; PubMed Central PMCID: PMCPmc4006270.
  8. 8. Gomes NM, Ryder OA, Houck ML, Charter SJ, Walker W, Forsyth NR, et al. Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. Aging cell. 2011;10(5):761–8. Epub 2011/04/27. pmid:21518243; PubMed Central PMCID: PMCPmc3387546.
  9. 9. Gorbunova V, Seluanov A. Coevolution of telomerase activity and body mass in mammals: from mice to beavers. Mechanisms of ageing and development. 2009;130(1–2):3–9. pmid:18387652; PubMed Central PMCID: PMC3733351.
  10. 10. Seluanov A, Chen Z, Hine C, Sasahara TH, Ribeiro AA, Catania KC, et al. Telomerase activity coevolves with body mass not lifespan. Aging cell. 2007;6(1):45–52. Epub 2006/12/19. pmid:17173545; PubMed Central PMCID: PMCPmc2693359.
  11. 11. Okuda K, Bardeguez A, Gardner JP, Rodriguez P, Ganesh V, Kimura M, et al. Telomere length in the newborn. Pediatric research. 2002;52(3):377–81. Epub 2002/08/24. pmid:12193671.
  12. 12. Youngren K, Jeanclos E, Aviv H, Kimura M, Stock J, Hanna M, et al. Synchrony in telomere length of the human fetus. Human genetics. 1998;102(6):640–3. Epub 1998/08/14. pmid:9703424.
  13. 13. Kimura M, Gazitt Y, Cao X, Zhao X, Lansdorp PM, Aviv A. Synchrony of telomere length among hematopoietic cells. Experimental hematology. 2010;38(10):854–9. Epub 2010/07/06. pmid:20600576; PubMed Central PMCID: PMCPmc3142672.
  14. 14. Daniali L, Benetos A, Susser E, Kark JD, Labat C, Kimura M, et al. Telomeres shorten at equivalent rates in somatic tissues of adults. Nature communications. 2013;4:1597. pmid:23511462; PubMed Central PMCID: PMC3615479.
  15. 15. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. American journal of human genetics. 1994;55(5):876–82. Epub 1994/11/01. pmid:7977349; PubMed Central PMCID: PMCPmc1918314.
  16. 16. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension. 2000;36(2):195–200. Epub 2000/08/19. pmid:10948077.
  17. 17. Vasa-Nicotera M, Brouilette S, Mangino M, Thompson JR, Braund P, Clemitson JR, et al. Mapping of a major locus that determines telomere length in humans. American journal of human genetics. 2005;76(1):147–51. Epub 2004/11/03. pmid:15520935; PubMed Central PMCID: PMCPmc1196417.
  18. 18. Hjelmborg JB, Dalgard C, Moller S, Steenstrup T, Kimura M, Christensen K, et al. The heritability of leucocyte telomere length dynamics. Journal of medical genetics. 2015;52(5):297–302. pmid:25770094; PubMed Central PMCID: PMC4413805.
  19. 19. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet (London, England). 2004;363(9408):507–10. Epub 2004/02/21. pmid:14975611.
  20. 20. Vasan RS, Demissie S, Kimura M, Cupples LA, Rifai N, White C, et al. Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Circulation. 2008;117(9):1138–44. Epub 2008/02/13. pmid:18268147; PubMed Central PMCID: PMCPmc3142671.
  21. 21. Hunt SC, Chen W, Gardner JP, Kimura M, Srinivasan SR, Eckfeldt JH, et al. Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. Aging cell. 2008;7(4):451–8. Epub 2008/05/09. pmid:18462274; PubMed Central PMCID: PMCPmc2810865.
  22. 22. Hansen ME, Hunt SC, Stone RC, Horvath K, Herbig U, Ranciaro A, et al. Shorter telomere length in Europeans than in Africans due to polygenetic adaptation. Human molecular genetics. 2016. Epub 2016/03/02. pmid:26936823.
  23. 23. De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Van Criekinge W, De Backer GG, et al. Paternal age at birth is an important determinant of offspring telomere length. Human molecular genetics. 2007;16(24):3097–102. Epub 2007/09/21. pmid:17881651.
  24. 24. Hjelmborg JB, Dalgard C, Mangino M, Spector TD, Halekoh U, Moller S, et al. Paternal age and telomere length in twins: the germ stem cell selection paradigm. Aging cell. 2015;14(4):701–3. pmid:25865872; PubMed Central PMCID: PMC4531084.
  25. 25. Kimura M, Cherkas LF, Kato BS, Demissie S, Hjelmborg JB, Brimacombe M, et al. Offspring's leukocyte telomere length, paternal age, and telomere elongation in sperm. PLoS Genet. 2008;4(2):e37. Epub 2008/02/20. pmid:18282113; PubMed Central PMCID: PMCPmc2242810.
  26. 26. Unryn BM, Cook LS, Riabowol KT. Paternal age is positively linked to telomere length of children. Aging cell. 2005;4(2):97–101. Epub 2005/03/18. pmid:15771613.
  27. 27. Cherkas LF, Aviv A, Valdes AM, Hunkin JL, Gardner JP, Surdulescu GL, et al. The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging cell. 2006;5(5):361–5. pmid:16856882.
  28. 28. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet (London, England). 2005;366(9486):662–4. pmid:16112303.
  29. 29. Du M, Prescott J, Kraft P, Han J, Giovannucci E, Hankinson SE, et al. Physical activity, sedentary behavior, and leukocyte telomere length in women. American journal of epidemiology. 2012;175(5):414–22. pmid:22302075; PubMed Central PMCID: PMC3282876.
  30. 30. Kark JD, Goldberger N, Kimura M, Sinnreich R, Aviv A. Energy intake and leukocyte telomere length in young adults. The American journal of clinical nutrition. 2012;95(2):479–87. pmid:22237065; PubMed Central PMCID: PMC3260074.
  31. 31. Schaakxs R, Wielaard I, Verhoeven JE, Beekman AT, Penninx BW, Comijs HC. Early and recent psychosocial stress and telomere length in older adults. International psychogeriatrics / IPA. 2016;28(3):405–13. pmid:26265356.
  32. 32. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(49):17312–5. pmid:15574496; PubMed Central PMCID: PMC534658.
  33. 33. Akkad A, Hastings R, Konje JC, Bell SC, Thurston H, Williams B. Telomere length in small-for-gestational-age babies. BJOG: an international journal of obstetrics and gynaecology. 2006;113(3):318–23. Epub 2006/02/21. pmid:16487204.
  34. 34. Factor-Litvak P, Susser E, Kezios K, McKeague I, Kark JD, Hoffman M, et al. Leukocyte Telomere Length in Newborns: Implications for the Role of Telomeres in Human Disease. Pediatrics. 2016. Epub 2016/03/11. pmid:26969272.
  35. 35. Steenstrup T, Hjelmborg JV, Kark JD, Christensen K, Aviv A. The telomere lengthening conundrum—artifact or biology? Nucleic acids research. 2013;41(13):e131. Epub 2013/05/15. pmid:23671336; PubMed Central PMCID: PMCPmc3905906.
  36. 36. Benetos A, Kark JD, Susser E, Kimura M, Sinnreich R, Chen W, et al. Tracking and fixed ranking of leukocyte telomere length across the adult life course. Aging cell. 2013;12(4):615–21. Epub 2013/04/23. pmid:23601089; PubMed Central PMCID: PMCPmc3798089.
  37. 37. Dalgard C, Benetos A, Verhulst S, Labat C, Kark JD, Christensen K, et al. Leukocyte telomere length dynamics in women and men: menopause vs age effects. International journal of epidemiology. 2015;44(5):1688–95. pmid:26385867; PubMed Central PMCID: PMC4681111.
  38. 38. Sidorov I, Kimura M, Yashin A, Aviv A. Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth. Experimental hematology. 2009;37(4):514–24. Epub 2009/02/14. pmid:19216021.
  39. 39. Aviv A, Kark JD, Susser E. Telomeres, atherosclerosis, and human longevity: a causal hypothesis. Epidemiology. 2015;26(3):295–9. pmid:25774608; PubMed Central PMCID: PMC4381978.
  40. 40. Hunt SC, Kark JD, Aviv A. Association between shortened leukocyte telomere length and cardio-metabolic outcomes. Circulation Cardiovascular genetics. 2015;8(1):4–7. pmid:25691684.
  41. 41. Codd V, Mangino M, van der Harst P, Braund PS, Kaiser M, Beveridge AJ, et al. Common variants near TERC are associated with mean telomere length. Nature genetics. 2010;42(3):197–9. Epub 2010/02/09. pmid:20139977; PubMed Central PMCID: PMCPmc3773906.
  42. 42. Levy D, Neuhausen SL, Hunt SC, Kimura M, Hwang SJ, Chen W, et al. Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(20):9293–8. Epub 2010/04/28. pmid:20421499; PubMed Central PMCID: PMCPmc2889047.
  43. 43. Mangino M, Christiansen L, Stone R, Hunt SC, Horvath K, Eisenberg DT, et al. DCAF4, a novel gene associated with leucocyte telomere length. Journal of medical genetics. 2015;52(3):157–62. pmid:25624462; PubMed Central PMCID: PMC4345921.
  44. 44. Mangino M, Hwang SJ, Spector TD, Hunt SC, Kimura M, Fitzpatrick AL, et al. Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Human molecular genetics. 2012;21(24):5385–94. Epub 2012/09/25. pmid:23001564; PubMed Central PMCID: PMCPmc3510758.
  45. 45. Savage SA, Alter BP. The role of telomere biology in bone marrow failure and other disorders. Mechanisms of ageing and development. 2008;129(1–2):35–47. pmid:18160098; PubMed Central PMCID: PMC2278290.
  46. 46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. pmid:21376230.
  47. 47. Campisi J. Cancer, aging and cellular senescence. In vivo. 2000;14(1):183–8. pmid:10757076.
  48. 48. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78–81. pmid:25554788; PubMed Central PMCID: PMC4446723.
  49. 49. Wu S, Powers S, Zhu W, Hannun YA. Substantial contribution of extrinsic risk factors to cancer development. Nature. 2016;529(7584):43–7. pmid:26675728; PubMed Central PMCID: PMCPMC4836858.
  50. 50. Peto R. Epidemiology, multistage models, and short-term mutagenicity tests. Orig Hum Cancer. 1977;4:1403–28.
  51. 51. Noble R, Kaltz O, Hochberg ME. Peto's paradox and human cancers. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2015;370(1673). pmid:26056357; PubMed Central PMCID: PMC4581036.
  52. 52. Gorbunova V, Seluanov A, Zhang Z, Gladyshev VN, Vijg J. Comparative genetics of longevity and cancer: insights from long-lived rodents. Nature reviews Genetics. 2014;15(8):531–40. pmid:24981598; PubMed Central PMCID: PMC4353926.
  53. 53. Abegglen LM, Caulin AF, Chan A, Lee K, Robinson R, Campbell MS, et al. Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans. JAMA. 2015;314(17):1850–60. pmid:26447779; PubMed Central PMCID: PMCPMC4858328.
  54. 54. Savage SA, Gadalla SM, Chanock SJ. The long and short of telomeres and cancer association studies. Journal of the National Cancer Institute. 2013;105(7):448–9. pmid:23468461; PubMed Central PMCID: PMC3614507.
  55. 55. Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, et al. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer epidemiology. 2013;37(4):434–9. pmid:23523330; PubMed Central PMCID: PMC3679277.
  56. 56. Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer research. 2011;71(21):6758–63. pmid:22028319; PubMed Central PMCID: PMC3206204.
  57. 57. Machiela MJ, Hsiung CA, Shu X, Seow WJ, Wang Z, Matsuo K, et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. International journal of cancer Journal international du cancer. 2014. pmid:25516442.
  58. 58. Seow WJ, Cawthon RM, Purdue MP, Hu W, Gao YT, Huang WY, et al. Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. Cancer research. 2014;74(15):4090–8. Epub 2014/05/24. pmid:24853549; PubMed Central PMCID: PMCPmc4119534.
  59. 59. Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, et al. Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer research. 2014;74(9):2476–86. pmid:24618342; PubMed Central PMCID: PMC4357479.
  60. 60. Pellatt AJ, Wolff RK, Torres-Mejia G, John EM, Herrick JS, Lundgreen A, et al. Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study. Genes, chromosomes & cancer. 2013;52(7):595–609. pmid:23629941; PubMed Central PMCID: PMC3807250.
  61. 61. Qu S, Wen W, Shu XO, Chow WH, Xiang YB, Wu J, et al. Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women's Health Study. American journal of epidemiology. 2013;177(7):617–24. Epub 2013/02/28. pmid:23444102; PubMed Central PMCID: PMCPmc3657533.
  62. 62. Lynch SM, Major JM, Cawthon R, Weinstein SJ, Virtamo J, Lan Q, et al. A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. International journal of cancer Journal international du cancer. 2013;133(11):2672–80. Epub 2013/05/16. pmid:23674344.
  63. 63. Julin B, Shui I, Heaphy CM, Joshu CE, Meeker AK, Giovannucci E, et al. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. British journal of cancer. 2015;112(4):769–76. Epub 2015/01/07. pmid:25562437; PubMed Central PMCID: PMC4333493.
  64. 64. Berg JJ, Coop G. A population genetic signal of polygenic adaptation. PLoS Genet. 2014;10(8):e1004412. Epub 2014/08/08. pmid:25102153; PubMed Central PMCID: PMCPmc4125079.
  65. 65. Pritchard JK, Pickrell JK, Coop G. The genetics of human adaptation: hard sweeps, soft sweeps, and polygenic adaptation. Current biology: CB. 2010;20(4):R208–15. pmid:20178769; PubMed Central PMCID: PMC2994553.
  66. 66. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science. 2014;346(6212):945–9. pmid:25414302.
  67. 67. Elias PM, Williams ML. Re-appraisal of current theories for the development and loss of epidermal pigmentation in hominins and modern humans. Journal of human evolution. 2013;64(6):687–92. pmid:23478159; PubMed Central PMCID: PMC3654079.
  68. 68. Osborne DL, Hames R. A life history perspective on skin cancer and the evolution of skin pigmentation. American journal of physical anthropology. 2014;153(1):1–8. pmid:24459698.
  69. 69. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957;11:398–411.
  70. 70. D'Mello MJ, Ross SA, Briel M, Anand SS, Gerstein H, Pare G. Association between shortened leukocyte telomere length and cardiometabolic outcomes: systematic review and meta-analysis. Circulation Cardiovascular genetics. 2015;8(1):82–90. pmid:25406241.
  71. 71. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. Bmj. 2014;349:g4227. Epub 2014/07/10. pmid:25006006; PubMed Central PMCID: PMCPmc4086028.
  72. 72. Wann LS, Thompson RC, Allam AH, Finch CE, Zink A, Frohlich B, et al. Atherosclerosis: a longue duree approach. Global heart. 2014;9(2):239–44. pmid:25667094.
  73. 73. El-Telbany A, Ma PC. Cancer genes in lung cancer: racial disparities: are there any? Genes & cancer. 2012;3(7–8):467–80. pmid:23264847; PubMed Central PMCID: PMC3527990.
  74. 74. Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. Journal of surgical oncology. 2013;107(1):1–7. pmid:22589078; PubMed Central PMCID: PMC4159073.
  75. 75. Metcalfe C, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, et al. Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study. British journal of cancer. 2008;99(7):1040–5. pmid:18797456; PubMed Central PMCID: PMC2567092.
  76. 76. Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nature reviews Cancer. 2015;15(4):248–54. pmid:25673085.
  77. 77. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113(1):30–7. pmid:16365194.
  78. 78. Hunt SC, Kimura M, Hopkins PN, Carr JJ, Heiss G, Province MA, et al. Leukocyte telomere length and coronary artery calcium. The American journal of cardiology. 2015;116(2):214–8. pmid:25960381; PubMed Central PMCID: PMC4475426.